<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473250</url>
  </required_header>
  <id_info>
    <org_study_id>#7056</org_study_id>
    <nct_id>NCT02473250</nct_id>
  </id_info>
  <brief_title>Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging</brief_title>
  <official_title>Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for subjects with a diagnosis of bipolar disorder who have depression at the&#xD;
      time of recruitment. It involves brain imaging with an MRI (magnetic resonance imaging) and&#xD;
      PET scan (positron emission tomography) and treatment with an antidepressant. The medication&#xD;
      involves adding an SSRI (either celexa/citalopram or prozac/fluoxetine) to a mood stabilizer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bipolar disorder is associated with alterations of chemicals in the brain, including one&#xD;
      named serotonin. Treatment of depression in bipolar disorder can be accomplished by&#xD;
      increasing serotonin function by medications named selective serotonin reuptake inhibitors&#xD;
      (SSRI's). Serotonin signals in the brain occur through receptors in a way that is similar to&#xD;
      a lock and key, where serotonin is a key and the receptor is a lock. One important receptor&#xD;
      is the serotonin 1A (5-HT1A) receptor. This receptor has been found to be abnormal in bipolar&#xD;
      disorder during periods of depression, as measured by a type of brain imaging called positron&#xD;
      emission tomography (PET). The amount of brain 5-HT1A receptor measured by imaging has also&#xD;
      been associated with how well depressed patients with major depressive disorder respond to an&#xD;
      SSRI medication. This project will measure the 5-HT1A receptors in bipolar depressed&#xD;
      individuals using PET with the radiotracer [11C]-CUMI-101 and will evaluate the ability of&#xD;
      this brain imaging signal to predict how patients respond to SSRI treatment when added to a&#xD;
      mood stabilizer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Depression severity. Minimum=0, Maximum=60. Higher numbers correspond to greater depression severity. The percent change between week 0 and the last observation was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Anxiety severity. Minimum=0, Maximum=56. The larger the value on the scale, the more intense the anxiety. The percent difference between week 0 and the last observation was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measure of manic symptoms. Minimum=0, Maximum=60. The higher the value on the scale, the more intense the manic symptoms. The maximum value of YMRS over the six week clinical trial is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-1</measure>
    <time_frame>6 weeks</time_frame>
    <description>General impression of symptoms by clinician. Minimum=1, Maximum=7. The higher value on the scale, the more symptomatic the patient is. The percent difference between week 0 and the last observation was calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Bipolar depressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).</description>
    <arm_group_label>Bipolar depressed</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.</description>
    <arm_group_label>Bipolar depressed</arm_group_label>
    <other_name>Celexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Diagnosis of bipolar I disorder or bipolar II disorder and currently meet criteria for&#xD;
             a major depressive episode&#xD;
&#xD;
          -  Patients who were on psychiatric medication at presentation will have failed that&#xD;
             regimen, as defined as not achieving at least partial remission after an adequate dose&#xD;
             of medication for at least six weeks.&#xD;
&#xD;
          -  Depression of sufficient severity to score at least 16 on the first 17 items of the&#xD;
             Hamilton Depression Rating Scale&#xD;
&#xD;
          -  Age range 18-60 years&#xD;
&#xD;
          -  Females of child-bearing potential must be willing to use an acceptable method of&#xD;
             birth control throughout the study.&#xD;
&#xD;
          -  Subject agrees to discontinue all psychotropic other than those in the PSF and other&#xD;
             types of drugs likely to interact with the 5-HT1A receptors.&#xD;
&#xD;
          -  Subject is likely to tolerate medication cross-taper to monotherapy with a mood&#xD;
             stabilizer (valproate, lamotrigine or lithium).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any other major psychiatric disorders such as lifetime schizophrenia,&#xD;
             schizoaffective disorder, current psychotic depression or current drug or alcohol&#xD;
             abuse (within two months before the study) or recent drug or alcohol dependence&#xD;
             (within six months before the study); anorexia nervosa or bulimia nervosa within the&#xD;
             last year; IV drug use of ecstasy use more than three times. Meet criteria for a manic&#xD;
             episode at the time of screening.&#xD;
&#xD;
          -  Previous failed trial of fluoxetine and citalopram by themselves or in combination&#xD;
             with an anti-manic agent, defined as at least six weeks of treatment at the dose of 20&#xD;
             mg per day or more. Failure of two trials of any SSRI or SNRI antidepressant&#xD;
             medications.&#xD;
&#xD;
          -  If the patients are discontinuing medications as part of the washout period or are&#xD;
             starting valproate, previous failed trial of mood stabilizer that they will take&#xD;
             alone.&#xD;
&#xD;
          -  Experienced intolerable side effects of both citalopram and fluoxetine in the past. If&#xD;
             the subject is not on medications, intolerable side effects of valproate in the past.&#xD;
&#xD;
          -  History of clinical deterioration when any of the medications that the patient is&#xD;
             taking at presentation have been discontinued in the past with the exception of any&#xD;
             medications that will be continued during the research protocol.&#xD;
&#xD;
          -  A first-degree family history of schizophrenia if the subject is less than 33 years&#xD;
             old&#xD;
&#xD;
          -  Significant active physical illness, including blood dyscrasias, lymphomas,&#xD;
             hypersplenism, endocrinopathies, renal failure, chronic obstructive lung disease,&#xD;
             autonomic neuropathies, peripheral vascular disease, malignancy&#xD;
&#xD;
          -  Actively suicidal, as defined by expressing ideation with a plan for suicide or&#xD;
             develops suicidal ideation that requires immediate medication or treatment&#xD;
             intervention.&#xD;
&#xD;
          -  Pregnancy, abortion or miscarriage in the two months prior to enrollment or plans to&#xD;
             conceive during the course of study participation&#xD;
&#xD;
          -  Lactating women&#xD;
&#xD;
          -  ECT within the past 6 months&#xD;
&#xD;
          -  Subjects who endorse a history of prior head trauma and score 1.5 standard deviations&#xD;
             below the mean on Trail-making A &amp; B will be excluded from study participation.&#xD;
&#xD;
          -  Metal implants, pacemaker, metal prostheses, metal orthodontic appliances or shrapnel&#xD;
             in the body&#xD;
&#xD;
          -  Current, past or anticipated exposure to radiation, including:&#xD;
&#xD;
               -  Having been badged for radiation exposure in the workplace&#xD;
&#xD;
               -  Participation in nuclear medicine protocols in the last year. Subjects will be&#xD;
                  eligible, however, if the injected dose and dosimetry of the radiotracer are&#xD;
                  known and the cumulative annual exposure of the previous study and this study is&#xD;
                  lower than the annual limit for research subjects defined by the FDA (21 CFR&#xD;
                  361.1)&#xD;
&#xD;
          -  History of claustrophobia that would prevent the participation in imaging scans&#xD;
&#xD;
          -  Current anticoagulant or anti-platelet treatment other than aspirin&#xD;
&#xD;
          -  Obesity with weight &gt;350 lbs or inability to fit into the MRI scanner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Lan, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bipolarimaging.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <results_first_submitted>February 11, 2021</results_first_submitted>
  <results_first_submitted_qc>March 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2021</results_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Martin Lan</investigator_full_name>
    <investigator_title>Clinical Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02473250/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02473250/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bipolar Depressed</title>
          <description>Bipolar depressed subjects had neuroimaging and treatment with a selective serotonin reuptake inhibitor in combination with a mood stabilizer. Fluoxetine was offered first, but citalopram was offered as an alternative if fluoxetine was not clinically appropriate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not tolerate medication washout</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Antidepressant effect of divalproex</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bipolar Depressed</title>
          <description>Bipolar depressed subjects had neuroimaging and treatment with a selective serotonin reuptake inhibitor in combination with a mood stabilizer. Fluoxetine was offered first, but citalopram was offered as an alternative if fluoxetine was not clinically appropriate.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg Depression Rating Scale</title>
        <description>Depression severity. Minimum=0, Maximum=60. Higher numbers correspond to greater depression severity. The percent change between week 0 and the last observation was calculated.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Depressed</title>
            <description>Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)&#xD;
Fluoxetine: Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).&#xD;
Citalopram: Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale</title>
          <description>Depression severity. Minimum=0, Maximum=60. Higher numbers correspond to greater depression severity. The percent change between week 0 and the last observation was calculated.</description>
          <units>Percent change in MADRS from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.24" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Rating Scale</title>
        <description>Anxiety severity. Minimum=0, Maximum=56. The larger the value on the scale, the more intense the anxiety. The percent difference between week 0 and the last observation was calculated.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Depressed</title>
            <description>Bipolar depressed subjects had neuroimaging and treatment with a selective serotonin reuptake inhibitor in combination with a mood stabilizer. Fluoxetine was offered first, but citalopram was offered as an alternative if fluoxetine was not clinically appropriate.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Anxiety Rating Scale</title>
          <description>Anxiety severity. Minimum=0, Maximum=56. The larger the value on the scale, the more intense the anxiety. The percent difference between week 0 and the last observation was calculated.</description>
          <units>Percent change in HAMA score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.95" spread="70.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Young Mania Rating Scale</title>
        <description>Measure of manic symptoms. Minimum=0, Maximum=60. The higher the value on the scale, the more intense the manic symptoms. The maximum value of YMRS over the six week clinical trial is reported.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Depressed</title>
            <description>Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)&#xD;
Fluoxetine: Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).&#xD;
Citalopram: Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale</title>
          <description>Measure of manic symptoms. Minimum=0, Maximum=60. The higher the value on the scale, the more intense the manic symptoms. The maximum value of YMRS over the six week clinical trial is reported.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-1</title>
        <description>General impression of symptoms by clinician. Minimum=1, Maximum=7. The higher value on the scale, the more symptomatic the patient is. The percent difference between week 0 and the last observation was calculated.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Depressed</title>
            <description>Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)&#xD;
Fluoxetine: Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).&#xD;
Citalopram: Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-1</title>
          <description>General impression of symptoms by clinician. Minimum=1, Maximum=7. The higher value on the scale, the more symptomatic the patient is. The percent difference between week 0 and the last observation was calculated.</description>
          <units>Percent change in CGI score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.17" spread="25.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the time that the participants were enrolled in the study. This time range varied depending on the research procedures performed. If all research procedures were performed, the participants were enrolled for 11 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bipolar Depressed</title>
          <description>Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)&#xD;
Fluoxetine: Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).&#xD;
Citalopram: Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Hospitalization</sub_title>
                <description>Two patients required psychiatric hospitalization during the study</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin Lan MD PhD</name_or_title>
      <organization>Columbia University Irving Medical Center</organization>
      <phone>646 774 7610</phone>
      <email>martin.lan@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

